Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol for Preventing Stroke-Associated Pneumonia in Intracerebral Hemorrhage
NCT07528235Phase 1Not yet recruiting
- Sponsor
- Tangdu Hospital
- Start
- May 2026
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of propranolol in pneumonia, sponsored by Tangdu Hospital. Primary endpoints: Maximum Tolerated Dose at 7 days, Adverse Events at 7 days and 1 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
propranolol
03
Conditions
pneumonia
Beyond the preview
Go deeper on NCT07528235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07528235.